MedTrace Logo

Comparing Safety and Efficacy of Amlodipine Verses S Amlodipine in Patients With Essential Hypertension

NCT04554303 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 80

Last updated 2020-11-12

No results posted yet for this study

Summary

As a third-generation dihydropyridine calcium channel blocker (CCB), Amlodipine is mainly used in a single therapy or combined therapy for hypertension or angina.

Edema, one of the most common side effects of dihydropyridine CCB formulations, may lead to drug control or discontinuation of drugs.

This clinical study intends to assess the safety and efficacy of S-amlodipine, which is assessed to be superior to Amlodipine in the aspects of antihypertensive effect and side effects, in edema of patients with essential hypertension.

Conditions

  • Essential Hypertension

Interventions

DRUG

S-amlodipine 2.5mg

Oral administration, 1 tablet per day

DRUG

Amlodipine 5mg

Oral administration, 1 tablet per day

Sponsors & Collaborators

  • Korea University Guro Hospital

    collaborator OTHER

  • Dt&Sanomedics

    collaborator INDUSTRY

  • Ahn-Gook Pharmaceuticals Co.,Ltd

    lead INDUSTRY

Principal Investigators

  • Eung Ju Kim, PhD · Korea University Guro Hospital

Eligibility

Min Age
19 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-10-28
Primary Completion
2022-05-23
Completion
2022-05-23
FDA Drug
Yes

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04554303 on ClinicalTrials.gov